Cited 12 time in
Ophthalmic dosage forms for drug delivery to posterior segment
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Jaemin | - |
| dc.contributor.author | Rhee, Yun-Seok | - |
| dc.date.accessioned | 2022-12-26T07:21:17Z | - |
| dc.date.available | 2022-12-26T07:21:17Z | - |
| dc.date.issued | 2022-03 | - |
| dc.identifier.issn | 2093-5552 | - |
| dc.identifier.issn | 2093-6214 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/1592 | - |
| dc.description.abstract | Background Degenerative ocular diseases such as macular retinopathy and retinal disorders significantly affect vision loss and the quality of life. The prevalence of these ophthalmic diseases is increasing due to surges in the elderly population and diabetes mellitus. Ophthalmic drug delivery systems for intraocular drug delivery have been studied and developed for decades. Due to multiple barriers in the eye, including physiological and anatomic obstacles, many challenges remain for enhanced ocular drug delivery. Currently, only a few approaches are available to treat ocular diseases. Area covered This review investigated various barriers in the eye and the current ocular formulations such as intravitreal injections and intravitreal implants. In addition, different types of advanced ophthalmic drug delivery systems, including lens implants, microneedle arrays, micropumps, nano-formulations, sonophoresis, and transscleral iontophoresis, were briefly reviewed. Expert opinion Novel ophthalmic dosage forms for drug delivery to the posterior segment should be developed to achieve a safe therapeutic effect. If some achievements can be established in further studies, the paradigm of chronic ocular diseases can be shifted to home-based self-administration, thus improving the therapeutic efficacy and the patient's quality of life. | - |
| dc.format.extent | 13 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국약제학회 | - |
| dc.title | Ophthalmic dosage forms for drug delivery to posterior segment | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1007/s40005-021-00554-8 | - |
| dc.identifier.scopusid | 2-s2.0-85123619644 | - |
| dc.identifier.wosid | 000749082900001 | - |
| dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.52, no.2, pp 161 - 173 | - |
| dc.citation.title | Journal of Pharmaceutical Investigation | - |
| dc.citation.volume | 52 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 161 | - |
| dc.citation.endPage | 173 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART002821432 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | GENE-TRANSFER | - |
| dc.subject.keywordPlus | SUPRACHOROIDAL SPACE | - |
| dc.subject.keywordPlus | VITREOUS BODY | - |
| dc.subject.keywordPlus | EYE | - |
| dc.subject.keywordPlus | INTRAVITREAL | - |
| dc.subject.keywordPlus | ULTRASOUND | - |
| dc.subject.keywordPlus | SURFACE | - |
| dc.subject.keywordPlus | NANOTECHNOLOGY | - |
| dc.subject.keywordPlus | IONTOPHORESIS | - |
| dc.subject.keywordPlus | MICRONEEDLES | - |
| dc.subject.keywordAuthor | Posterior segment | - |
| dc.subject.keywordAuthor | Degenerative ocular disease | - |
| dc.subject.keywordAuthor | Ocular | - |
| dc.subject.keywordAuthor | Drug delivery | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
